CRVS
Price
$7.42
Change
+$0.52 (+7.54%)
Updated
Dec 17, 04:59 PM (EDT)
78 days until earnings call
CYTK
Price
$47.77
Change
-$1.24 (-2.53%)
Updated
Dec 17, 04:59 PM (EDT)
64 days until earnings call
Ad is loading...

CRVS vs CYTK

Header iconCRVS vs CYTK Comparison
Open Charts CRVS vs CYTKBanner chart's image
Corvus Pharmaceuticals
Price$7.42
Change+$0.52 (+7.54%)
Volume$32.82K
CapitalizationN/A
Cytokinetics
Price$47.77
Change-$1.24 (-2.53%)
Volume$21.74K
CapitalizationN/A
CRVS vs CYTK Comparison Chart
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. CYTK commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Hold and CYTK is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (CRVS: $7.39 vs. CYTK: $47.78)
Brand notoriety: CRVS and CYTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 117% vs. CYTK: 117%
Market capitalization -- CRVS: $474.86M vs. CYTK: $5.64B
CRVS [@Biotechnology] is valued at $474.86M. CYTK’s [@Biotechnology] market capitalization is $5.64B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileCYTK’s FA Score has 1 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • CYTK’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTK is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 4 TA indicator(s) are bullish while CYTK’s TA Score has 3 bullish TA indicator(s).

  • CRVS’s TA Score: 4 bullish, 6 bearish.
  • CYTK’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CRVS is a better buy in the short-term than CYTK.

Price Growth

CRVS (@Biotechnology) experienced а -7.86% price change this week, while CYTK (@Biotechnology) price change was -5.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.83%. For the same industry, the average monthly price growth was +1.09%, and the average quarterly price growth was +9.71%.

Reported Earning Dates

CRVS is expected to report earnings on Mar 06, 2025.

CYTK is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-4.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($5.64B) has a higher market cap than CRVS($475M). CRVS YTD gains are higher at: 319.886 vs. CYTK (-42.772). CRVS has higher annual earnings (EBITDA): -25M vs. CYTK (-481.94M). CYTK has more cash in the bank: 1.01B vs. CRVS (41.7M). CRVS has less debt than CYTK: CRVS (354K) vs CYTK (790M). CYTK has higher revenues than CRVS: CYTK (3.22M) vs CRVS (0).
CRVSCYTKCRVS / CYTK
Capitalization475M5.64B8%
EBITDA-25M-481.94M5%
Gain YTD319.886-42.772-748%
P/E RatioN/AN/A-
Revenue03.22M-
Total Cash41.7M1.01B4%
Total Debt354K790M0%
FUNDAMENTALS RATINGS
CRVS vs CYTK: Fundamental Ratings
CRVS
CYTK
OUTLOOK RATING
1..100
625
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
5248
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3557
P/E GROWTH RATING
1..100
981
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRVS's Valuation (86) in the Pharmaceuticals Major industry is in the same range as CYTK (100) in the Biotechnology industry. This means that CRVS’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (48) in the Biotechnology industry is in the same range as CRVS (52) in the Pharmaceuticals Major industry. This means that CYTK’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as CYTK (100) in the Biotechnology industry. This means that CRVS’s stock grew similarly to CYTK’s over the last 12 months.

CRVS's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as CYTK (57) in the Biotechnology industry. This means that CRVS’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for CRVS (98) in the Pharmaceuticals Major industry. This means that CYTK’s stock grew significantly faster than CRVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSCYTK
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 6 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 13 days ago
80%
Bullish Trend 8 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 6 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
N/A
View a ticker or compare two or three
Ad is loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EWZ24.000.39
+1.66%
iShares MSCI Brazil ETF
WRND30.24N/A
N/A
NYLI Global Equity R&D Leaders ETF
GURU51.62-0.31
-0.60%
Global X Guru™ ETF
XSW202.23-1.37
-0.67%
SPDR® S&P Software & Services ETF
FTXN28.60-0.20
-0.69%
First Trust Nasdaq Oil & Gas ETF

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with VRDN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then VRDN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
+7.10%
VRDN - CRVS
38%
Loosely correlated
-3.34%
FULC - CRVS
34%
Loosely correlated
+2.71%
VCYT - CRVS
33%
Poorly correlated
-2.52%
CYTK - CRVS
32%
Poorly correlated
-2.53%
KROS - CRVS
32%
Poorly correlated
-7.31%
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with KRON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then KRON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-2.53%
KRON - CYTK
43%
Loosely correlated
-0.39%
IOVA - CYTK
42%
Loosely correlated
-0.38%
DARE - CYTK
42%
Loosely correlated
+0.31%
CKPT - CYTK
41%
Loosely correlated
+9.59%
DSGN - CYTK
40%
Loosely correlated
-0.64%
More